Original Research Article

DOI: https://dx.doi.org/10.18203/2349-3933.ijam20214876

Colorectal cancer in younger adults (<50 years); a retrospective study on its clinicopathological characteristics

J. Kannan, Deepak George, Srigopal Mohanty*, N. Ingersal, Amit Saklani

Department of Medical Oncology, Government Royapettah Hospital and Kilpauk Medical College, Chennai, Tamil Nadu, India

Received: 20 November 2021 Revised: 09 December 2021 Accepted: 13 December 2021

*Correspondence:

Dr. Srigopal Mohanty,

E-mail: drsrigopal17@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Colorectal cancer (CRC) is a common cancer worldwide with significant geographical variation in its incidence. CRC among young adults is not well reported in Indian patients.

Methods: A retrospective study was performed to determine the burden and to analyze the clinicopathological characteristics of newly diagnosed CRC among younger adults (<50 years). Chi-square method was used to analyze the clinicopathological characteristics. $P \le 0.05$ was considered statistically significant.

Results: CRC among younger adults comprised 40.3% of total patients median age of 40 years at diagnosis, was associated with predominantly male patients with male: female ratio of 1.8:1, positive family history, lesser comorbidities (p=0.000), majority left sided primary tumor with left: right ratio of 4.6:1, more frequent high grade histology compared to older age group (p=0.000), advanced primary tumor and nodal metastasis. Approximately one third patients had distant metastasis at diagnosis compared to in one fourth patients in older patients. Peritoneal metastasis was significantly higher among younger adults compared to older patients (p=0.000). Significantly greater proportion of patients among younger adults initially presented with bowel obstruction (p=0.034), for which upfront emergency surgical procedures was performed in significantly higher proportion of patients compared to the older age group (p=0.007).

Conclusions: Advanced stage and aggressive disease biology of CRC in younger adult warrants inclusion of one decade younger age group into present screening recommendation.

Keywords: Clinicopathology, Colorectal cancer, Metastasis, Younger adults

INTRODUCTION

Globally colorectal cancers (CRC) account for approximately 10% of all cancer incidence, and 9.4% of all cancer mortality. It is the 3rd most common cancer in incidence and 2nd most common in cancer mortality. It is 5th most common cancer in India accounting for 4.9% of all cancer incidence. The highest incidence of CRC in India has been reported to be from south India. Risk factors of CRC are broadly divided into genetic, environmental or life style related factors. Due to aggressive screening practices of the population more than 50 years of age the number of colorectal cancers are

decreasing in older age group, whereas there is a dramatic increase in incidence among younger adults aged 20 to 49. CRC in young adults are commonly diagnosed in advanced stage.^{8,9} In view of paucity of data on CRC among younger adults in Indian patients, we conducted a retrospective study to estimate the burden and to analyze the characteristics of CRC among younger adults.

METHODS

A retrospective analytical study was conducted for newly diagnosed CRC patients treated in the department of Medical oncology, Government Royapettah hospital

attached to Kilpauk Medical College, Chennai. Convenient sampling method was followed to include 305 newly diagnosed CRC patients registered in the centre between January 2016 and December 2020. The study aimed to determine the burden of CRC among younger adults, and to evaluate its clinicopathological characteristics. Patients were divided into two arms, i.e. the younger adults (<50 years) and the older age group (\geq 50 years).

Data was retrieved from the cancer registry in a predesigned proforma after obtaining permission from institutional ethical committee. Data was collected for clinicopathological variables like age, sex, smoking, alcohol history, co-morbidity, performance status, family history, presenting symptoms, duration of symptoms, histopathology, grade, site, types of lesion, bowel obstruction, emergency surgery, tumor stage, nodal stage, metastasis, site and number of distant metastasis. SPSS statistical software version 23.0 was used for data analysis. Chi square analysis was used to compare different clinicopathological parameters between the two arms. A two tailed p value ≤0.05 was considered statistically significant.

Inclusion criteria

Patients with newly diagnosed biopsy proven colorectal cancer registered in the hospital between January 2016 and December 2020 were included in the study.

Exclusion criteria

Patients with colorectal lesion without biopsy proof or those with recurrent colorectal cancer were excluded from the study.

RESULTS

Out of total 305 newly diagnosed CRC patients, the younger adults constituted 123 (40.3%). The median age at diagnosis was 54 years and 40 years for overall patients and younger adults respectively. Predominantly male patients were observed in the study population with male to female ratio (M: F) of 1.6:1, and 1.8:1 among overall patients and younger adults respectively. Most patients (approximately two third) presented with eastern cooperative oncology group (ECOG) performance status I (Table 1). Family history of colorectal cancer or polyps was present in two patients, both of which belonged to the younger adults group. The most common presenting symptoms were in the following order; bleeding perrectum> pain abdomen> altered bowel habit> vomiting (Table 1). Most of the primary tumor were left sided, with left to right sided tumor ratio of 4:1, 4.6:1, and 3.8:1, in the overall, younger age, and older age groups respectively. Adenocarcinoma and intermediate grade histology was most commonly seen; whereas significantly higher frequency of higher grade histology was found in younger age group (Table 2). Greater than 90% of patients were diagnosed with advanced T stage (T3/T4) and over 80% patients had lymph nodal metastasis at diagnosis, both findings were similar in the two age groups (Table 2). Distant metastasis was observed in approximately one fourth of total patients, out of which majority (96%) were detected at multiple sites and numbers. Relatively higher number of distant metastasis was observed among younger patients (Table 2). Common sites of distant metastasis were in the following order; liver> peritoneum> lung> bone> brain> others (Table 1). Peritoneal metastasis was found to be significantly more common among younger age patients, whereas no such difference was observed between the two arms for other site metastasis (Table 2).

Table 1: Clinicopathological characteristics of the study population.

Parameters	Number (%)
Age (in years)	
Median	54
Range	20-92
Sex	
Male	189 (62)
Female	116 (38)
Smoking	
Yes	57 (18.7)
No	248 (81.3)
Alcohol	
Yes	59 (19.4)
No	246 (80.6)
ECOG	
I	210 (68.8)
II	87 (28.5)
III	8 (2.7)
IV	-
Co morbidities	
Diabetes	30 (9.8)
Hypertension	32 (10.4)

Continued.

Coronary artery disease	Parameters	Number (%)
HIV 1 (0.3) Psystive family history 2 (0.7) Symptoms Pain abdomen 122 (40) Bleeding per rectum 178 (58.4) Altered bowel habit 104 (34.1) Vomiting 36 (11.8) Duration of symptoms (in months) Wedian 2 Range 1-60 Site Site Site Uccroprolificative 117 (64.6) Ulceroprolificative 108 (35.4) Intestinate 508 (28.2) No 197 (35.1) Emergency surgery Fes 198 (62.8) No 219 (71.8) Histopathology Adenocarcinoma 291 (95.6) Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Adeno squamous 1 (1.3) Fig. 198 (1.4) Low 103 (33.9) Intertrad squamous 1 (1.6) Intertr		
Hypothysoid 1 (0.3)		
Positive family history 2 (0.7) Symptoms Family history Symptoms Family history Symptoms Family history Symptoms Family history Family hi		
Symptoms		
Pain abdomen		2 (0.1)
Bleeding per rectum		122 (40)
Altered howel habit 104 (34.1) Vomiting 36 (11.8) Duration of symptoms (in months) Median 2		
Vomiting		
Duration of symptoms (in months)		
Median 2		50 (11.0)
Range 1-60 Site		2
Site Righted sided colon 60 (19.7) Left sided colon 79 (25.9) Rectum 166 (54.4) Type of lesion Ulceroproliferative 197 (64.6) Ulceroproliferative 108 (35.4) Intestinal obstruction Yes 198 (64.9) No 107 (35.1) Emergency surger Yes 86 (28.2) No 219 (71.8) Histopathology Histopathology Adenocarinoma 291 (95.6) Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Frame diate 151 (49.4) High 51 (16.7) Tumor stage Tumor stage <td></td> <td></td>		
Righted sided colon 60 (19.7) Left sided colon 79 (25.9) Rectum 166 (54.4) Type of lesion Ulceroproliferative 197 (64.6) Ulceroproliferative 108 (35.4) Intestinal obstruction Yes 198 (64.9) No 107 (35.1) Emergency surgery Yes 86 (28.2) No 219 (71.8) Histopathology Adenocarcinoma 291 (95.6) Neuroendocrinoma 291 (95.6) Neuroendocrinoma 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adenos squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) Nodal stage		1-00
Left sided colon 79 (25.9) Rectum 166 (54.4) Type of lesion Ulceroproliferative 197 (64.6) Ulceroproliferative 198 (35.4) Intestinal obstruction *** Yes 198 (64.9) No 107 (35.1) Emergency surgery *** Yes 86 (28.2) No 219 (71.8) Histopathology *** Adenocarcinoma 291 (95.6) Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 10 (3) Grade *** Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage *** T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage *** Negative 60 (19.7) </td <td></td> <td>60 (10 7)</td>		60 (10 7)
Rectum		
Type of lesion		
Ulceroinfiltrative		100 (34.4)
Intestinal obstruction		107 (64.6)
Nestinal obstruction	Ulceropromerative	
Yes 198 (64.9) No 107 (35.1) Emergency surgery Yes 86 (28.2) No 219 (71.8) Histopathology ————————————————————————————————————		106 (33.4)
No		109 (64 0)
Emergency surgery Yes		
Yes 86 (28.2) No 219 (71.8) Histopathology Adenocarcinoma 291 (95.6) Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage 80 (20.2) Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3)		107 (33.1)
No 219 (71.8) Histopathology Adenocarcinoma 291 (95.6) Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (7.2) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3)		96 (29.2)
Histopathology		
Adenocarcinoma 291 (95.6) Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Uow Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 3 (10 (68.8) 4 69 (22.7) Nodal stage Nogative Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Sites of distant metastasis 222 (7.2) Pertioneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal		219 (71.8)
Neuroendocrine 3 (1) Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Townstage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage 80 (19.7) Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Oligometastasis 3 (1) Soligometastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Sites of of (4) 1 Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) <td></td> <td>201 (05 ()</td>		201 (05 ()
Lymphoma 2 (0.7) Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage 80 Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Oligometastasis 3 (1) Oligometastasis 30 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Sites of distant metastasis 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6		
Melanoma 4 (1.3) GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 5 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Liver 50 (16.4) Lung 22 (7.2) Pertioneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
GIST 2 (0.7) Adeno squamous 1 (0.3) Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage TI 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Adeno squamous 1 (0.3) Grade 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage 80 (20.2) Negative 60 (19.7) Positive 245 (80.3) Distant metastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Sites of distant metastasis 10 (3.3) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Grade Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Sites of distant metastasis 22 (72.8) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Abdominal wall 2 (0.6)		
Low 103 (33.9) Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		1 (0.3)
Intermediate 151 (49.4) High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		102 (22.0)
High 51 (16.7) Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Tumor stage T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis No metastasis Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
T1 4 (1.3) T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		51 (16.7)
T2 22 (7.2) T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 222 (72.8) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		4 (1.2)
T3 210 (68.8) T4 69 (22.7) Nodal stage Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		` /
T4 69 (22.7) Nodal stage 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Nodal stage 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis 22 (72.8) Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Negative 60 (19.7) Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		69 (22.7)
Positive 245 (80.3) Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		<0 (10 T)
Distant metastasis Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Oligometastasis 3 (1) Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		245 (80.3)
Multiple metastasis 80 (26.2) No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		2 (1)
No metastasis 222 (72.8) Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Sites of distant metastasis Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Liver 50 (16.4) Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		<i>LLL</i> (/2.8)
Lung 22 (7.2) Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		50 (16.4)
Peritoneum 27 (8.9) Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Bone 10 (3.3) Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Brain 8 (2.6) Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Ovary 1 (0.3) Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Adrenal 1 (0.3) Spleen 3 (1) Abdominal wall 2 (0.6)		
Spleen 3 (1) Abdominal wall 2 (0.6)		
Abdominal wall 2 (0.6)		
Urinary bladder 1 (0.3)		
	Urinary bladder	1 (0.3)

Table 2: Comparison of different clinicopathological parameters between two age groups.

Parameters	<50 years N (%)	≥50 years N (%)	P value
Sex			
Male	71 (57.7)	117 (64.3)	
Female	52 (42.3)	64 (35.2)	0.339
Co-morbidities	, ,		0.000
(DM-2/HTN/CAD/hypothyroid/HIV)	116 (40.6)	170 (59.4)	0.000
Alcohol	26 (21.7)	30 (17.9)	0.421
Smoking	25 (20.3)	32 (17.6)	0.547
Family history	2 (1.8)	-	0.092
Histopathology			
Adenocarcinoma	113 (94.9)	171 (96.6)	
Lymphoma	2 (1.7)	-	
Melanoma	1 (0.8)	3 (1.7)	0.407
Adeno squamous	1 (0.8)	-	
GIST	1 (0.8)	1 (0.6)	
Neuroendocrine	1 (0.8)	1 (0.6)	
Grade	· · ·		
Low	25 (22.9)	67 (41.4)	0.000
Intermediate	56 (51.4)	78 (48.1)	0.000
High	28 (25.7)	17 (10.5)	
Site of tumor			
Left sided	101 (82.1)	144 (79.1)	0.519
Right sided	22 (17.9)	38 (20.9)	
Bowel obstruction at initial presentation	52 (42.3)	56 (30.8)	0.039
Upfront emergency surgery	45 (36.6)	41 (22.5)	0.007
Tumor stage			
T1	1 (0.8)	4 (1.7)	0.248
T2	5 (4.3)	16 (9.1)	
T3	78 (67.2)	122 (69.3)	
T4	32 (27.6)	34 (19.3)	
Nodal stage			
Positive	102 (82.9)	147 (80.8)	0.633
Negative	21 (17.1)	35 (19.2)	
Distant metastasis			
Oligometastasis	-	3 (1.6)	0.127
Multiple metastasis	38 (30.9)	42 (23.1)	
Sites of distant metastasis			
Liver	19 (15.4)	31 (17)	0.714
Lung	10 (22.7)	12 (24.5)	0.842
Peritoneum		9 (4 4)	0.001
	19 (15.4)	8 (4.4)	0.001
Bone	19 (15.4) 5 (13.5)	5 (12.2)	0.862

DISCUSSION

The present study was conducted to estimate the burden of CRC among younger adults, and to analyze its epidemiology, clinical presentation, stages at the time of diagnosis, the pattern of metastasis. The median age of diagnosis of CRC in the study was 54 years, which was lower than the global data of median age at diagnosis of 66 years. ¹⁰ Present study revealed that 40.3% patients were

below 50 years of age, which was in concordance with the study finding of Ghodssi-Ghassemabad et al and Sudharsan et al. 11,12 Men were more affected than women (62% versus 38% respectively) in the study, which was in concordance with previous Indian study report by Patil et al. 13 The smoking and diabetes are the important risk factors of colorectal cancers; but in this study small no patients were smokers and diabetes mellitus, which could be probably due to prior undetected diabetes and or information bias. 14,15 About 70% of patients had ECOG

performance status of 1. The most common presenting symptom was lower GI bleeding, followed by abdominal pain which was almost same in both the age groups. This study showed 42.3% of younger patients initially presented with intestinal obstruction which was significantly more in comparison to older patients. Among younger adults, 36.6% had undergone emergency surgery for the same which was also significantly higher compared to older age patients. Previous study have reported that usually 5 to 10% of colorectal cancer patients have familial history, but in the present study, positive family history was found in 1.8% patients; which was similar with study finding of Patil et al, who have reported familial CRC in 1.9% patients. ^{13,16,17}

The most common site of the lesion was in rectum followed by left colon and right colon in both the age groups, which was similar to that of previous study report. Most common pathologic variant was adenocarcinoma, which was same as that of previous studies. Significantly higher frequency of high grade tumor was found among younger adults compared to the older patients, which was in concordance with previous studies. 18,19

Nearly one third of patients among younger adults and one fourth patients in the older age group had de-novo metastasis. Liver metastasis was the commonest site of distant metastasis in overall population and also in both the age groups; whereas there was significantly increased rate of peritoneal metastasis among younger adults, these results were similar with other previous studies. ²⁰ Majority of patients had multiple metastasis at diagnosis, whereas all metastatic patients among younger adults had multiple metastasis.

Limitations

It was a single institutional and retrospective study. The difference in survival characteristics between the two age groups was not evaluated in the study.

CONCLUSION

Younger adults comprised 40.3% of total CRC patients. It is associated with predominantly male patients, positive family history, majority left sided primary tumor, more frequently high grade histology compared to older patients, advanced stage at diagnosis. Approximately one third patients had distant metastasis at diagnosis, compared to one fourth in the older age group. Peritoneal metastasis was more common among young adults. Greater proportion of patients among younger adults initially presented with bowel obstruction, for which upfront emergency surgical procedures was performed in significantly higher proportion among younger adults compared to the older age group. In view of high burden of CRC among young adults and its advanced stage at diagnosis, inclusion of these patients in routine screening

practice is required for early diagnosis and treatment to improve outcome.

Funding: No funding sources Conflict of interest: None declared

Ethical approval: The study was approved by the

Institutional Ethics Committee

REFERENCES

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
- World health Organization (WHO). International Agency for Research on Cancer. India factsheet. Lyon: IARC. 2020. Available at: https://gco.iarc.fr/today/data/factsheets/populations/ 356-india-fact-sheets.pdf. Accessed on 25 August 2021.
- 3. NCRP. Three year report of the population based cancer registries. National cancer registry programme, Indain council of medical research (ICMR), Bangalore, India. 2016.
- Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331(25):1669-74.
- Ponz de Leon M, Scapoli C, Zanghieri G, Sassatelli R, Sacchetti C, Barrai I. Genetic transmission of colorectal cancer: exploratory data analysis from a population based registry. J Med Genet. 1992;29(8):531-8.
- 6. Singh PN, Fraser GE. Dietary risk factors for colon cancer in a low-risk population. Am J Epidemiol. 1998;148(8):761-74.
- 7. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990;323(24):1664-72.
- 8. Davis DM, Marcet JE, Frattini JC, Prather AD, Mateka JJ, Nfonsam VN. Is it time to lower the recommended screening age for colorectal cancer? J Am Coll Surg. 2011;213(3):352-61.
- 9. Lee PY, Fletcher WS, Sullivan ES, Vetto JT. Colorectal cancer in young patients: characteristics and outcome. Am Surg. 1994;60(8):607-12.
- Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER web site, April 2019. Available at: https://seer.cancer.gov/csr/1975_2016/. Accessed on 25 August 2021.
- Ghodssi-Ghassemabadi, R., Hajizadeh, E., Kamian, S, Mahmoudi M. Clinicopathological features and survival of colorectal cancer patients younger than 50 years: a retrospective comparative study. J Egypt Natl Canc Inst. 2019;31:6.

- 12. Sudarshan V, Hussain N, Gahine R, Mourya J. Colorectal cancer in young adults in a tertiary care hospital in Chhattisgarh, Raipur. Indian J Cancer. 2013;50:337-40.
- Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De'Souza A, Chopra S, Bal M. Colorectal Cancer in India: An Audit from a Tertiary Center in a Low Prevalence Area. Indian J Surg Oncol. 2017;8(4):484-90.
- Gong J, Hutter C, Baron JA, Berndt S, Caan B, Campbell PT, et al. A pooled analysis of smoking and colorectal cancer: timing of exposure and interactions with environmental factors. Cancer Epidemiol Biomarkers Prev. 2012;21(11):1974-85.
- 15. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106(11):1911-21.
- Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331(25):1669-74.
- Pariente A, Milan C, Lafon J, Faivre J. Colonoscopic screening in first-degree relatives of patients with

- 'sporadic' colorectal cancer: a case-control study. The Association Nationale des Gastroentérologues des Hôpitaux and Registre Bourguignon des Cancers Digestifs (INSERM CRI 9505). Gastroenterology. 1998;115(1):7-12.
- 18. Zhao L, Bao F, Yan J, Liu H, Li T, Chen H, et al. Poor prognosis of young patients with colorectal cancer: a retrospective study. Int J Color Dis. 2017;32(8):1147-56.
- 19. Yeo S, Chew M, Koh P, Tang C. Young colorectal carcinoma patients do not have a poorer prognosis: a comparative review of 2,426 cases. Tech Coloproctol. 2013;17(6):653-61.
- 20. Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. World J Gastroenterol. 2012;18(39):5489-94.

Cite this article as: Kannan J, George D, Mohanty S, Ingersal N, Saklani A. Colorectal cancer in younger adults (<50 years); a retrospective study on its clinicopathological characteristics. Int J Adv Med 2022;9:25-30.